search icon
      blog search icon

      Atreca, Inc. (BCEL) Stock Surged 5.07% Pre-Market, Here’s Why - Stocks Telegraph

      By Iqra Jamal

      Published on

      October 4, 2021

      10:06 AM UTC

      Last Updated on

      October 4, 2021

      12:44 PM UTC

      Atreca, Inc. (BCEL) Stock Surged 5.07% Pre-Market, Here’s Why - Stocks Telegraph

      Atreca, Inc. (BCEL) stock soared 5.07% in the pre-market trading session at the price of $6.43 following the announcement of two upcoming presentations at the SITC 2021 Annual Meeting in Washington from 10 to 14th November 2021. BCEL is an oncology-related biopharmaceutical company. It discovers, develops, and commercializes novel antibody immuno-therapeutics using its differentiated discovery program. These antibodies provide the framework for its first-in-class therapeutic leading product candidate, ATRC-101. 

      BCEL to present at Society for Immunotherapy of Cancer (SITC) Annual Meeting 

      On 1st October 2021, BCEL published two upcoming poster presentations from 10th to 14th November 2021 at the SITC 2021 Annual Meeting in Washington, D.C.  

      The first presentation title is “First-in-Human Results with the Novel Tumor-Targeting Antibody ATRC-101: Phase 1b Study in Patients with Solid Tumors”. The presentation with poster number 518 will be held from 12th to 13th November 2021 from 7:00 a.m. to 8:30 p.m. ET. The second presentation title is “Preclinical Evaluation of Pegylated Liposomal Doxorubicin or Doxorubicin with mATRC-101 in the EMT6 Syngeneic Mouse Model”. This presentation with poster number 559 will be held from 12th to 14th November 2021 from 7:00 a.m. to 8:30 p.m. ET.  

      The full abstract will get published on the SITC website on Tuesday, 9th November 2021, at 8:00 a.m. ET. The posters will be available on the BCEL’s official website on 12th November 2021 at 7:00 a.m. ET.  

      BCEL Reported Second Quarter 2021 Financial Results 

      On 11th August 2021, BCEL published its earnings report for the second quarter ended 30th June 2021 and provided corporate updates. CEO of BCEL, John Orwin, remarked that they have published the initial data from the dose-escalation portion of the “Phase 1b trial of ATRC-101”. As per the outcomes, ATRC-101 is well-tolerated in the study. Its initial positive signs of activity provided a strong rationale for further evaluation. The company looks forward to presenting updated data on the early-stage pipeline in the coming future, he added.  

      Second Quarter 2021 Financial Summary 

      As of 30th June 2021, the cash, cash equivalents, and short-term investments were approximately $182.3 million. BCEL reported research and development expenses of $19.0 million for the three months ended on 30th June 2021. They included $1.9 million in a non-cash share-based compensation expense. For the three months ended on 30th June 2021, the reported general and administrative costs were $8.0 million. They included $2.0 million in a non-cash share-based compensation expense. For the three months ended on 30th June 2021, the company reported a net loss of $26.7 million. Basic and diluted net loss per share attributable to common stockholders was $0.72 as of 30th June 2021. 

      More From Stocks telegraph